Skip to content

Sareum Holdings: CEO Tim Mitchell talks about his COVID research pipeline

Sareum Holdings: CEO Tim Mitchell talks about his COVID research pipeline

Early-stage pharma developer Sareum Holdings (AIM:SAR) is making good progress on its pipeline of projects, justifying the share price rise increases earlier this year.

With Covid spreading damage particularly hard in the UK in the early months of 2021 shares rocketed to 8.85 pence in August – from 220 pence at the end of 2020 – as investors' focus zeroed in on the company’s research on a molecule that could be used to treat breathing complications caused by the virus.


Want the full story? Start a free trial of The Armchair Trader Plus+ today.

Get weekly investment ideas and tips that will take your investing to the next level. Sign up here.

Free 28 day trial. Cancel anytime.


Log In or Sign Up to Armchair Trader+

Already a member? Log in here:


Not a member? Sign up now or see the membership benefits

Further content of this article is not available as it is for members only. Please visit the registration page for Armchair Trader Plus+ for further details on the benefits of becoming a member.

Share this article

Invest with these platforms

Hargreaves Lansdown

IG

Interactive Brokers

Interactive Investor

Charles Stanley

IG

Interactive Brokers

Charles Stanley

Looking for great investing ideas? Get our free newsletter.

This article does not constitute investment advice.  Do your own research or consult a professional advisor.

Learn with our free 'How to' Guides

Our latest in-depth company reports

On the podcast

Sign up for great investing stock tips

Thanks to our Site Partners

Our partners are established, regulated businesses and we are grateful for their support.

Aquis
CME Group
FP Markets
Pepperstone
Schroders

aberdeen
WisdomTree
ARK
Plus500
CMC Markets
Back To Top